ArticleDiabetology & metabolic syndrome2026
Association between estimated glucose disposal rate and sarcopenia in U.S. adults: a cross-sectional study based on NHANES 2011-2018.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe estimated glucose disposal rate (eGDR) is a novel indicator of insulin resistance that reflects the body's ability to process glucose. The association between eGDR and sarcopenia in adults remains unclear. This study investigated the relationship between eGDR and sarcopenia to support the improved clinical identification of the condition.
methodsWe analysed data from the 2011 to 2018 cycles of the National Health and Nutrition Examination Survey (NHANES). The final analytical sample comprised 7,147 participants. After applying survey weights, the population was 49.5% male and 50.5% female. We first calculated the weighted prevalence of sarcopenia among U.S. adults. Participants were then stratified into four groups based on eGDR quartiles. A weighted multivariate logistic regression model assessed the association between eGDR and sarcopenia risk, whereas a restricted cubic spline (RCS) examined their dose-response relationship. Subgroup analyses with interaction tests verified the stability of this association, and mediation analysis identified potential factors underlying the relationship.
resultsA total of 7147 adult participants were included in this study. The weighted prevalence of sarcopenia was 6.7%, and the proportion of sarcopenic obesity among patients with sarcopenia was 73.1%. Weighted multivariate logistic regression revealed an obvious inverse association between eGDR and sarcopenia. In the fully adjusted model, compared with the lowest eGDR quartile group, the adjusted odds ratios (95% confidence intervals) for sarcopenia in quartiles 2nd to 4th quartile groups were 0.70 (95% CI: 0.52, 0.95; p < 0.001), 0.35 (95% CI: 0.25, 0.50; p < 0.001), and 0.12 (95% CI: 0.08, 0.18; p < 0.001), respectively. Subgroup analyses and interaction tests indicated that this relationship was not affected by factors such as age, sex, race, marital status, education, smoking, or drinking. Mediation analysis confirmed the mediating roles of inflammatory indices in the association between eGDR and sarcopenia (p < 0.001).
conclusionA negative relationship was observed between eGDR and sarcopenia prevalence. The inflammatory response may mediate this relationship. eGDR may serve as a potential biomarker for the early identification and diagnosis of sarcopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.